Alzheimer’s blockbuster might spur investor bonanza, higher medicare costs

The Alzheimer’s drug data released Tuesday night aren’t only going to be transformative for Biogen, which has been struggling to get love from investors after its botched launch of Aduhelm.

Source link

Leave a Comment

Your email address will not be published. Required fields are marked *

%d bloggers like this: